TEST203, 130 centres Current AMR Commercially Organism Hospital In Various n/a Website, 215 from surveillance funded by centres/ antimicrobial and participating Pfizer Inc. laboratories susceptibility of Gram-negative countries defined isolates strains publications (US, Latin collected from America, patients with a Europe and documented Asia) infection to glycylcycline, tigecycline, and comparator antimicrobials MYSTIC46, Worldwide Inactive Longitudinal Commercially Organism Hospital centres In vitro Gram-positive n/a Website, 130, 203, medical AMR funded by (e.g. cystic antimicrobial and 204, 207, centres surveillance AstraZeneca fibrosis, susceptibility of strains 213, 216 actively study (AMR International neutropaenic meropenem and publications (part of prescribing trends and ICUs, and comparator GAARD) meropenem among general wards) antimicrobials meropenem against various and Gram-positive common and pathogens; strains antimicrobial usage patterns)
TEST203, 215 130 centres from participating countries (US, Latin America, Europe and Asia) Current AMR surveillance Commercially funded by Pfizer Inc. Organism Hospital centres/ laboratories In antimicrobial susceptibility of defined isolates collected from patients with a documented infection to glycylcycline, tigecycline, and comparator antimicrobials Various and Gram-negative strains n/a Website, publications MYSTIC46, 130, 203, 204, 207, 213, 216 (part of GAARD) Worldwide medical centres actively prescribing meropenem Inactive Longitudinal AMR surveillance study (AMR trends among meropenem and common pathogens; antimicrobial usage patterns) Commercially funded by AstraZeneca International Organism Hospital centres (e.g. cystic fibrosis, neutropaenic and ICUs, and general wards) In vitro antimicrobial susceptibility of meropenem and comparator antimicrobials against various Gram-positive and strains Gram-positive and strains n/a Website, publications
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx